DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00042601

CompletedPhase 2

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

A Single Center, Randomized, Double-blind, Placebo-controlled, Two-period, Crossover Study Evaluating the Acute Effect of Pramlintide on Satiety and Food Intake in Normal-weight and Obese Non-diabetic Subjects and in Insulin Treated Subjects With Type 1 and Type 2 Diabetes Mellitus

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

1

Recruiting sites

—

Enrollment

51

actual

Study population

Healthy volunteers, Obesity / overweight, Type 1 diabetes, Type 2 diabetes

Key I/E criteria

•BMI 20-25•HbA1c 6.5-10%•Male

Primary endpoints

•Satiety of participants on Pramlintide•Food intake of participants on Pramlintide

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00042601
Org study ID137-149

Timeline

Milestones

Study first posted2002-08-05estimated
Last update posted2015-10-21estimated
Study start2002-07 (month precision)
Primary completion2003-10actual (month precision)
Study completion2003-10actual (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweightType 1 diabetesType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexMale
Healthy volunteersNot accepted

Eligibility criteria

For Healthy Volunteers:

•BMI >=20 to <=25kg/m2 or >=30 to <=40 kg/m2

For Subjects with Type 1 or Type 2 Diabetes:

•Treated with insulin for at least 6 months prior to screening
•HbA1c value between 6.5-10% inclusive
•BMI between 20-40kg/m2

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Other (unclassified)
1

Other clinical outcomes

2 endpoints
Primary/protocol endpoint/low confidence

Change in satiety of participants on Pramlintide

Time frame:2 Weeks

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in food intake of participants on Pramlintide

Time frame:2 Weeks

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Effect of pramlintide on postprandial metabolic and hormonal responses

Time frame:2 Weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.